Safety and Efficacy of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) in Craniofacial Surgery

Elie P. Ramly, MD
Allyson R. Alfonso, BS, BA
Rami S. Kantar, MD
Maxime M. Wang, BA
J. Rodrigo Diaz Siso, MD
Amel Ibrahim, MBBS, PhD
Paulo G. Coelho, DDS, PhD
Roberto L. Flores, MD

Introduction: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is one of the most commonly used osteogenic agents in the craniofacial skeleton. This study reviews the safety and efficacy of rhBMP-2 as applied to craniofacial reconstruction and assesses the level of scientific evidence currently available.

Methods: An extensive literature search was conducted. Randomized controlled trials (RCTs), case series and reports in the English language as well as Food and Drug Administration reports were reviewed. Studies were graded using the Oxford Center for Evidence-Based Medicine Levels of Evidence Scale. Data heterogeneity precluded quantitative analysis.

Results: Seventeen RCTs (Levels of evidence: Ib-Iib) were identified evaluating the use of rhBMP-2 in maxillary sinus, alveolar ridge, alveolar cleft, or cranial defect reconstruction (sample size: 7–160; age: 8–75 years). Study designs varied in rigor, with follow-up ranging 3–36 months, and outcome assessment relying on clinical exam, radiology, and/or histology. There was wide variation in rhBMP-2 concentrations, carriers, and controls. Most studies evaluating rhBMP-2 for cranial defect closure, mandibular reconstruction, or distraction osteogenesis consisted of retrospective cohorts and case reports. The evidence fails to support rhBMP-2 use in maxillary sinus wall augmentation, calvarial reconstruction, mandibular reconstruction, or distraction osteogenesis. RhBMP-2 may be effective in alveolar reconstruction in adults, but is associated with increased postoperative edema.

Conclusions: A risk–benefit ratio favoring rhBMP-2 over alternative substitutes remains to be demonstrated for most applications in plastic and reconstructive surgery. Long-term data on craniofacial growth is lacking, and using rhBMP-2 in patients younger than 18 years remains off-label.

(Plast Reconstr Surg Glob Open 2019;7:e2347; doi: 10.1097/GOX.0000000000002347; Published online 19 August 2019.)

Disclosure: The authors have no financial interest to declare in relation to the content of this article.
single-level anterior lumbar interbody fusion. FDA-approved indications subsequently expanded in 2004 to include the treatment of acute open tibial fractures, and in 2007, rhBMP-2 was approved as an alternative to autogenous bone grafting for sinus and localized alveolar ridge augmentation.

RhBMPs rapidly gained popularity; from 2002 to 2006, their use increased from 0.7% to 25% of all spine fusion procedures in the United States alone, with 85% of rhBMP use involving off-label applications. RhBMPs initially favorable safety profile was soon overshadowed by concern regarding complications associated with ectopic bone formation, osteolytic defects, carcinogenesis, wound complications, and in cases of anterior cervical spine use, severe soft tissue swelling, dysphagia, and respiratory compromise. This culminated in the issuance of a Public Health Notification by the FDA in 2008 alerting practitioners to those potentially life-threatening adverse events. Despite its cost and risk profile, rhBMP-2 continues to be used in various anatomical locations for FDA-approved and off-label applications. In contrast, rhBMP-7 (OP-1; Stryker Corporation, Kalamazoo, Mich.), which had initially received limited FDA approval under a Humanitarian Device Exemption for treatment of recalcitrant tibial nonunions, failed to gain FDA Premarket Approval in 2009 and its sales were eventually discontinued. This review thus focuses on the current use of rhBMP-2, with particular emphasis on its safety and efficacy in craniofacial applications.

METHODS

An extensive literature search was conducted in PubMed and the Cochrane Library by 2 independent reviewers (E.P.R. and A.R.A.), using the terms “bone morphogenetic protein,” “bone morphogenic protein,” “recombinant human bone morphogenetic protein,” “BMP,” “BMP-2,” “rhBMP-2.” Titles, abstracts, texts, and references were reviewed. Systematic reviews, randomized controlled trials (RCTs), prospective or retrospective case series, and case reports in the English language were included. Animal studies were excluded, as were clinical studies outside the craniofacial skeleton. Relevant publicly available FDA reports were reviewed. Studies were independently graded by 3 authors (E.P.R.; A.R.A.; and R.S.K.) using the Oxford Center for Evidence-Based Medicine Levels of Evidence Scale. Any discrepancy was resolved by discussion. Data heterogeneity precluded a quantitative analysis.

RESULTS

Seventeen RCTs [levels of evidence (LOEs): Ib-Iib] were identified (Sample size: 7–160; age: 8–75 years), including 5 evaluating the use of rhBMP-2 in maxillary sinus floor augmentation, 7 in localized alveolar ridge augmentation, 4 in alveolar cleft reconstruction (Table 1), and one in cranial defect closure (Table 2). Study designs varied in methodology and analysis, with follow-up ranging from 3 to 36 months, and outcome assessment relying on various combinations of clinical exam, plain radiography, computerized tomography (CT), and/or histologic evaluation. There was wide variation in rhBMP-2 concentrations (0.05–1.5 mg/mL) and carriers [Absorbable collagen sponge (ACS) ± bovine bone xenograft (Bio-Oss), Bio-Oss alone, biphasic calcium phosphate, hydroxyapatite granules, β-Tricalcium phosphate/hydroxyapatite (β-TCP/HA), demineralized bone matrix, or hydrogel]. Similarly, a variety of controls were used (autogenous bone graft ± allograft, Bio-Oss, ACS, β-TCP/HA, DBM, peristomialplasty, or no treatment). Systematic reviews and meta-analyses were significantly limited by the heterogeneity of the studies included, their lack of power, risk of bias, and inconsistent reporting of adverse events. The most notable side effect was prolonged severe edema. No statistically significant increase in infection, heterotopic ossification, malignant transformation, or airway compromise was found in studies evaluating the use of rhBMP-2 in craniofacial surgery. Five RCTs evaluated rhBMP-2 in maxillary sinus floor augmentation (n = 22–160; age ≥ 18 years) (Table 1). Two multicenter RCTs with 24–36 months follow-up compared rhBMP-2 to bone auto ± allograft controls and found equivalent histology but superior bone formation on CT and more successful implant placement and functional loading in the control groups. Three RCTs compared rhBMP-2 on different carriers to xenograft controls with varying results: a multicenter RCT reported significantly higher bone formation with rhBMP-2 based on histomorphometry at 3 months. A smaller study favored the xenograft control group on histomorphometry at 9 months. A multicenter RCT by Kim et al reported radiological and histological equivalence between rhBMP-2 and xenograft controls. Facial edema lasting up to 5 weeks with rhBMP-2 was reported in 3 of the 5 trials. Seven RCTs evaluated rhBMP-2 in alveolar ridge augmentation (n = 11–80; age ≥ 18 years) (Table 2). One single-center trial compared rhBMP-2 with mandibular autogenous bone graft and found no significant difference in bone formation using an analog caliper and cone-beam CT. Four studies favored rhBMP-2 over various controls including Bio-Oss, ACS, β-TCP/HA, or no treatment, using direct measurement, CT imaging, and/or histology. Two studies found no significant difference between rhBMP-2 and DBM or Bio-Oss controls. Facial edema lasting up to 2 weeks was more frequent and severe with rhBMP-2 exposure.

Of 4 RCTs comparing rhBMP-2 to iliac crest bone graft (ICBG) in alveolar cleft reconstruction (n = 7–21; age 8–16 years) (Table 1), the only trial with results favoring rhBMP-2 enrolled skeletally mature patients only (mean age 16 years). The study reported significantly higher estimated graft take in the rhBMP-2 group on intraoral examination, better bone healing, enhanced mineralization, and relative alveolar defect filling on Panorex and three-dimensional CT scans. Other trials included younger or skeletally immature participants; 2 trials reported equivalence between rhBMP-2 and ICBG controls on CT, while one favored ICBG controls. Severe orofacial edema was reported, occasionally resulting in wound dehiscence.
Reports of rhBMP-2 use in cranial defect closure included one RCT, whereas retrospective cohorts and case reports constituted the bulk of the evidence on mandibular reconstruction (DO). Successful bone formation was inconsistently achieved in cranial defect reconstruction, but more reliable in mandibular reconstruction and DO. More than half of the studies evaluating mandibular reconstruction noted significant edema. Dosing was not consistently documented in studies with lower LOE.

In the pediatric population, edema was also the most notable complication, occasionally necessitating steroid treatment or reoperation for rhBMP-2 implant removal.56 A retrospective series of patients treated for nontraumatic

### Table 1. Randomized Controlled Trials on the Use of rhBMP-2 in Maxillary Sinus, Alveolar Ridge, and Alveolar Cleft Reconstruction

| Clinical Application | References | Methodology | LOE | n | Age (y) | FU (mo) | Comparison | Efficacy (Bone Formation) | Adverse Events (rhBMP-2-related) |
|----------------------|------------|-------------|-----|---|---------|--------|------------|-------------------------|---------------------------------|
| Maxillary sinus augmentation | Boyne et al20 | PB-RCT (multicenter) | Ib | 48 | ≥18 | 36 | rhBMP-2 (0.75 mg/mL) + ACS versus rhBMP-2 (1.50 mg/mL) + ACS versus bone graft (auto ± allograft) | Favors control | Edema (dose dependent) |
| | Triplett et al20 | P-RCT (multicenter) | Ib | 160 | ≥18 | 24 | rhBMP-2 (1.5 mg/mL) + ACS versus bone graft (auto ± allograft) | Favors control | Edema |
| | Kao et al21 | P-RCT (number of centers NR) | Ib | 22 | ≥18 | 9 | rhBMP-2 (1.5 mg/mL) + ACS + Bio-Oss versus Bio-Oss alone | Favors control | None |
| | Kim et al22 | PB-RCT (multicenter) | Ib | 46 | >18 | 6 | rhBMP-2 (1.5 mg/mL) + BCP versus Bio-Oss | No difference | None |
| | Kim et al23 | PB-RCT (multicenter) | Ib | 147 | >18 | 3 | rhBMP-2 (1 mg/mL) + hydroxyapatite versus Bio-Oss | Favors rhBMP-2 | Edema (2–5 weeks) |
| Alveolar ridge augmentation | Jung et al24 | PB-RCT (single center) | Ib | 11 | 27–75 | 6 | rhBMP-2 (0.5 mg/mL) + Bio-Oss versus Bio-Oss | Favors rhBMP-2 | None |
| | Fiorellini et al25 | PB-RCT (multicenter) | Ib | 80 | 47.4 (mean) | 4 | rhBMP-2 (0.75 mg/mL) + ACS versus ACS alone versus no treatment | Favors rhBMP-2 (dose dependent) | Edema, erythema |
| | Huh et al26 | PB-RCT (multicenter) | Ib | 72 | 35–65 | 3 | rhBMP-2 (1.5 mg/mL) + β-TCP/HA versus β-TCP/HA | Favors rhBMP-2 | None |
| | De Freitas et al27 | P-RCT (single center) | Ib | 24 | ≥18 | 6 | rhBMP-2 (1.5 mg/mL) + ACS versus mandibular autogenous bone graft | No difference | Edema (2 weeks) |
| | Coomes et al28 | P-RCT (single center) | Ib | 39 | ≥18 | 5 | rhBMP-2 (1.5 mg/mL) + ACS versus ACS | Favors rhBMP-2 | Edema, erythema (10 d) |
| | Kim et al29 | PB-RCT (multicenter) | Ib | 69 | 20–70 | 3 | rhBMP-2 (0.05 mg/mL) + DBM gel versus DBM | No difference | None |
| | Nam et al30 | PB-RCT (single center) | Ib | 17 | 20–68 | 4 | rhBMP-2 (1 mg/mL) + hydroxyapatite versus Bio-Oss | No difference | Edema |
| Alveolar cleft | Dickinson et al31 | PB-RCT (single center) | Ib | 21 | 16 (mean) | 12 | rhBMP-2 (1.5 mg/ml) + ACS versus ICBG | Favors rhBMP-2 | None |
| | Alonso et al32 | PB-RCT (single center) | Ib | 16 | 8–12 | 12 | rhBMP-2 (1.5 mg/mL) + ACS versus ICBG | Favors control | Edema (in 37% of rhBMP-2 group) |
| | Canan et al33 | P-RCT (single center) | Ib | 18 | 8–15 | 12 | rhBMP-2 (1.5 mg/mL) + ACS versus ICBG versus peristosteoplasty | No difference between rhBMP-2 and ICBG; both superior to peristosteoplasty | None |
| | Neovius et al34 | P-RCT (single center) | Ib | 7 | 9.9 (mean) | 6 | rhBMP-2 (0.05 mg/mL + hydrogel versus 0.25 mg/mL + hydrogel versus ICBG) | No difference; dose-dependent response noted | Edema (2 weeks in higher dose group with associated wound dehiscence) |

β-TCP/HA, β-Tricalcium phosphate and hydroxyapatite; B, blinded; BCP, biphasic calcium phosphate; DBM, demineralized bone matrix; FU, follow-up; NR, not reported; P, prospective.
Table 2. Studies Describing the Use of rhBMP-2 in Cranial and Mandibular Defect Reconstruction

| Clinical Application | References | Indication | Methodology | LOE | n | Age (y) | FU (mo) | Intervention/Comparison | Conclusion | Adverse Events (rhBMP-2-related) |
|---------------------|------------|------------|-------------|-----|---|--------|--------|-------------------------|------------|----------------------------------|
| Cranial defect reconstruction | Arander, 2006 | Remote postsurgical infection and frontal bone loss | Case report | IV | 1 | 60 | 4 | rhBMP-2 + heparin + bovine collagen + hyaluronic acid + fibrin + ICBG | Ossification observed (insufficient yield) | None |
| | Shah et al | Metopic craniosynostosis | Case report | IV | 1 | 2 | 0.5 | rhBMP-2 + ACS (concentration NR) | rhBMP-2 implant removed at postoperative day 10 | Generalized scalp and facial edema, requiring steroids, antibiotics, reoperation, rhBMP-2 implant removal |
| | Skogh et al | Neurosurgical defects | P-RCT | IIb | 12 | 45–69 | 6 | rhBMP-2 + hydrogel versus hydrogel | rhBMP-2 not associated with enhanced bone growth | None |
| | Beidas et al | Nontraumatic defects | Retrospective case series | IV | 36 | 2–13 | 5–16 | rhBMP-2 + ACS versus cranial bone shavings | rhBMP-2 increased defect closure | Postoperative fusion of a previously patent cranial suture (9.5% of rhBMP-2 group) |
| Mandibular defect reconstruction | Jung et al | Edentulism | PB-RCT | IIb | 6/11 | 27–75 | 6 | rhBMP-2 + ACS + Bio-Os versus ACS + Bio-Os | rhBMP-2 enhanced maturation of the regenerated bone | None |
| | Carter et al | Trauma; nonunion; osteomyelitis; dentigerous cyst | Retrospective case series | IV | 5 | 41–81 | ≤22 | rhBMP-2 + ACS bone marrow cells and allogeneic cancellous bone chips versus ACS + rhBMP-2 | Restoration of the defect in 3/5 pts. Failures successfully treated with ICBG | Edema, nonunion, absence of bone regeneration, hardware failure |
| | Herford and Boyne | Neoplasia; osteomyelitis | Retrospective case series | IV | 14 | 10 | 6–18 | rhBMP-2 + ACS | Successful defect restoration and implant placement | Hardware exposure |
| | Balaji | Cyst | Case report | IV | 1 | 6 | 6 | rhBMP-2 + ACS + rib graft (autogenous) | Successful defect restoration | Edema |
| | Herford and Cicciù | Giant cell tumor | Case report | IV | 1 | 25 | 6 | rhBMP-2 + ACS | Successful defect restoration | NR |
| | Misch | Mandibular atrophy | Retrospective case series | IV | 5 | NR | 6 | rhBMP-2 + ACS + allograft | Bone formation on CT, low density | Edema |
| | Sweeney et al | Osteoradionecrosis | Retrospective case series | IV | 17 | 55.5 (mean) | 3–12 | rhBMP-2 + ACS | No difference | No difference in malunion, reoperation, swelling, or infection |
| | Cicciù et al | BRONJ | Retrospective case series | IV | 17/20 | NR | 6–12 | rhBMP-2 + ACS | Successful bone formation | NR |
| | Cicciù et al | Ameloblastoma | Case report | IV | 1 | 31 | 18 | rhBMP-2 + ACS + DBM | Successful defect restoration | Edema |
| | Balaji | Juvenile cemento-ossifying fibroma | Case report | IV | 1 | 1.5 | 36 | rhBMP-2 + ACS + rib graft (autogenous) | Successful defect restoration and implants placement | Edema |
| | Oliveira et al | Osteosarcoma; osteomyelitis; hypoplasia/failed distraction | Retrospective case series | IV | 3 | 1–57 | 6–12 | rhBMP-2 + ICBG or rhBMP-2 alone | Bone formation on CT | Edema |

B, blinded; BRONJ, bisphosphonate-related osteonecrosis of the jaw; DBM, demineralized bone matrix; FU: follow-up; NR, not reported; P, prospective.
cranial defects reported postoperative fusion of previously patent cranial sutures in 9.5% of patients exposed to rhBMP-2. 38

Of the 7 RCTs with results favoring rbmp-2, 5 (71%) reported no conflict of interest. One study did not include a disclosure statement, and one study reported funding by Medtronic. All 3 RCTs reporting equivalence between rhBMP-2 and autologous bone graft reported no conflict of interest.

**DISCUSSION**

**RhBMP-2 Dosing and Carrier Scaffolds**

Autologous bone graft is the treatment of choice for many defects of the craniofacial skeleton; however, bone graft has been associated with limited stock, absorption, donor site morbidity, and prolonged hospitalization. Bone substitutes and osteogenic agents such as hydroxyapatite, DBM, calcium phosphate-based synthetic materials, and BMP products have been proposed as potential therapies to circumvent the limitations of bone graft. 52,53 BMP has strong osteoinductive properties stimulating the proliferation, migration, and differentiation of mesenchymal stem cells into osteoblasts, and plays a role in regulating the expression of target genes involved in bone physiology. 5–7

Dosing and carriers are important considerations for effective and safe BMP administration. Although ACS is most commonly used, the optimal rhBMP-2 carrier has yet to be established. Numerous biomaterials have been suggested, including natural or synthetic biodegradable polymers, inorganic materials, and composites. 54,55 Carriers that suboptimally bind BMP may result in its release into tissues at high concentration. Thus, the dose-dependent increase in bone formation is to be balanced with a greater potential for adverse events. 2,19,25

**Maxillary Sinus Wall Augmentation**

The 5 RCTs evaluating rhBMP-2 in maxillary sinus floor augmentation were heterogeneous in design. 19–23 In 2 multicenter RCTs, efficacy was superior in the bone graft control group. 19,20 When xenograft was used as control, the only trial with results favoring rhBMP-2 had short follow-up and conclusions solely based on histologic parameters. Although facial edema lasting up to 5 postoperative weeks was reported, it did not result in airway compromise or dysphagia (Table 1). Boyne et al. 19 found that patients treated with higher (1.50 mg/mL) rhBMP-2 concentrations had significantly greater edema than those receiving 0.75 mg/mL rhBMP-2 or bone grafting (P < 0.05), denoting a dose-dependent correlation with adverse events. RhBMP-2 therefore does not offer substantial clinical benefit as a bone substitute in maxillary sinus wall augmentation, and is associated with significant postoperative edema.

**Alveolar Ridge Augmentation**

Only one trial compared rhBMP-2 to autogenous bone graft in alveolar ridge augmentation and found no significant difference in bone formation. In other trials, rhBMP-2 was superior to ACS and β-TCP/HA, but not DBM. Two small trials compared rhBMP-2 on different carriers to xenograft controls with varying results (Table 1). 24–30 Most trials used CT to measure bone growth. All trials were limited by short follow-up (3–6 months). Severe postoperative edema was again reported with rhBMP-2. de Freitas et al. 27 noted that recovery was twice longer for those patients, with edema preventing the use of a provisional prosthesis for 2 weeks postoperatively. The available evidence suggests that the efficacy of rhBMP-2 for alveolar ridge augmentation is superior to other bone substitutes and equivalent to bone graft, with the additional risk of prolonged postoperative edema.

**Alveolar Cleft Reconstruction**

RCTs investigating alveolar cleft reconstruction were the only ones to compare rhBMP-2 to bone graft controls in a craniofacial patient population below the age of 18 years. The only trial favoring rhBMP-2 over ICBG in terms of safety, efficacy, cost, and length of stay enrolled skeletally mature patients only. 31 Two additional trials including younger or skeletally immature participants reported equivalence between rhBMP-2 and ICBG. One RCT found results favoring ICBG.

Alonso et al. 32,56 reported facial edema in 37% of patients exposed to rhBMP-2 without superior bone formation. 35 Results from a large retrospective series including 414 patients receiving rhBMP-2/DBM or ICBG corroborate those findings, with no statistical difference in the canine eruption rate or reoperative alveolar cleft repair. 58 No difference was found in major or overall complications. One patient exposed to rhBMP-2 required prolonged intubation for intraoperative airway swelling, but this was deemed unrelated to the agent. Patients exposed to rhBMP-2 had more local/wound complications including edema (14% versus 1.65%; P < 0.0001). One of them required outpatient steroid treatment, whereas others had spontaneous resolution; 4.6% had dehiscence with no additional intervention needed in half of the cases. 58

The clinical data on the effect of rhBMP-2 on craniofacial growth are very limited. Studies by Alonso et al. 32,33 and Raposo-Amaral et al. 57,59 found no significant difference in nasal symmetry at 6 postoperative months, and no significant changes in upper lip and nostril anatomy or maxillary cephalometric proportions on three-dimensional CT at 1 year. Longer-term follow-up is lacking, and the studies had small sample sizes unequally randomized into rhBMP-2 and ICBG groups, with an even smaller number of patients undergoing imaging.

The evidence supporting the efficacy of rhBMP-2 in craniofacial bone formation is strongest in alveolar cleft reconstruction. However, in the absence of high-quality long-term data, the interaction of rhBMP-2 with skeletal growth remains to be elucidated. Caution is recommended as the use of rhBMP-2 in patients younger than 18 years of age remains off-label.

**Calvarial Defect Reconstruction**

Studies describing the use of rhBMP-2 in cranial defect reconstruction are included in Table 2. One RCT enrolled 12 patients (age range: 45–69), comparing rhBMP-2 on
hyaluronan-based hydrogel to controls for standardized critical-size cranial defects resulting from neurosurgery.67 For each patient in the treatment group, 4 craniotomy holes were treated with rhBMP-2/hydrogel (0.25 mg/mL), hydrogel alone, Spongostan (Ethicon) alone, or Tisseel (Baxter) mixed with bone autograft. In the control group, the holes were treated with Spongostan or Tisseel mixed with bone autograft. Bone healing was assessed with CT at 3–6 months. Comparing rhBMP-2/hydrogel to hydrogel alone without taking borehole location into account initially indicated somewhat superior healing with rhBMP-2, but a deeper analysis showed that this effect was confounded by a generally superior healing capacity in frontal compared to parietal-temporal bone, a finding that the study could not further investigate. No local or systemic adverse events were noted.

In a retrospective multicenter study including pediatric patients (age 2–13), Beidas et al38 found that compared to cranial bone shavings alone, bone graft with rhBMP-2/ACS resulted in increased closure of cranial defects. However, there was postoperative complete fusion of previously patent cranial sutures in 9.5% of patients exposed to rhBMP-2.38 Shah et al36 used rhBMP-2 with fronto-orbital advancement in a 2-year-old with metopic craniosynostosis. The patient developed generalized scalp, face, and anterior cervical edema albeit without evidence of airway compromise. He necessitated steroids and operative removal of the rhBMP-2 implants, with dramatic improvement in swelling. No signs of infection were noted and removal of the rhBMP-2 implants, with dramatic improvement in swelling. No signs of infection were noted and no signs of infection were noted and the adverse event was attributed to an immune-mediated response to rhBMP-2, consistent with the literature. Of note, studies have described transient elevation in anti-CD3 movement, or implant placement.63,64 Although initial reports seem encouraging, the efficacy and safety of rhBMP-2 in DO remain to be validated in large prospective series with longer-term follow-up.

Lessons Learned from the Use of rhBMP-2 in Spine and Orthopedic Surgery

The clinical experience with rhBMP-2 is richest in spine surgery.1,2 With the initial increase in rhBMP-2 use in the years following its FDA approval, a series of reports surfaced describing adverse events including heterotopic ossification, osteolysis, inflammatory complications, and malignancy.1,2 In the setting of cervical spine fusion, adverse events included retropharyngeal swelling, dysphagia, and respiratory compromise requiring postoperative intubation, tracheotomy, or surgical site drainage, prompting the issuance of a Public Health Notification by the FDA.3,14 No convincing evidence of similar severe rhBMP-2-related adverse events has been found in our extensive review of the craniofacial literature.

Carragee et al2 reviewed data from the original 13 industry-sponsored trials including 780 patients undergoing spine surgery with rhBMP-2. No rhBMP-2–associated adverse events had been reported in those publications. Comparative review of FDA documents and subsequent publications revealed significant inconsistencies, and the study concluded that the true estimate of adverse events associated with rhBMP-2 in spine fusion ranged 10%–50% depending on the surgical approach. Under the Yale University Open Data Access Project, patient-level data from the Medtronic-sponsored RCTs were obtained and reviewed by 2 independent teams, with meta-analyses pub-
lished in 2013.\textsuperscript{5,6} Both studies found rhBMP-2-related adverse events to be higher than initially reported, suggesting possible methodological flaws and potential bias.

Particularly relevant to the field of craniofacial surgery is rhBMP-2s safety profile in the pediatric population. RhBMP-2 use in patients under the age of 18 continues to be off-label. Therefore, there is also a lack of pediatric dosing recommendations. The orthopedic literature has several accounts of the use of rhBMP-2 in pediatric spine and long bone surgery. The studies report edema, dehiscence, hematoma, compartment syndrome, infection, and the need for reoperation in cases where rhBMP-2 was used, but the rates are close to those generally cited for those procedures. The potential role of rhBMP-2 is difficult to elucidate given the lack of adequate control and limited follow-up.\textsuperscript{6,7} Speculation on the long-term safety of rhBMP-2 continues, particularly regarding the risk of malignancy, with conflicting reports.\textsuperscript{7,8} There is however some physiological basis to substantiate concerns as BMP-2 plays many roles at the cellular level, and deviation from its physiologic expression has been associated with tumors involving the prostate, breast, oral mucosa, pleura, and bone.\textsuperscript{2} Additional high-quality long-term evidence is necessary to better assess the safety and efficacy of rhBMP-2 in adult and pediatric patients, and its long-term effect on craniofacial growth.

CONCLUSIONS

The safety profile of rhBMP-2 and the quality of evidence supporting its use are in development. The evidence does not support the use of rhBMP-2 in maxillary sinus wall augmentation and points against its use in calvarial reconstruction. There is insufficient evidence for the use of rhBMP-2 in mandibular reconstruction or DO. RhBMP-2 may be effective in alveolar ridge augmentation and alveolar cleft reconstruction in adults, but is associated with increased risk of postoperative edema. There is a lack of long-term data on craniofacial growth, and the use of rhBMP-2 in patients younger than 18 years of age remains off-label. A risk–benefit ratio favoring rhBMP-2 over alternative substances remains to be demonstrated for most applications relevant to plastic and reconstructive surgery.

Roberto L. Flores, MD

Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health
222 E 41st Street, 22nd Floor. New York, NY 10017
E-mail: Roberto.Flores@nyulangone.org

REFERENCES

1. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11:471–491.
2. James AW, LaChaud G, Shen J, et al. A review of the clinical side effects of bone morphogenetic protein-2. Tissue Eng Part B Rev. 2016;22:284–297.
3. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893–899.
4. Johnson EE, Urist MR, Finerman GA. Bone morphogenetic protein augmentation grafting of resistant femoral nonunions. A preliminary report. Clin Orthop Relat Res. 1988;May (230):257–265.
5. Bragdon B, Moseychuk O, Saldanha S, et al. Bone morphogenetic proteins: a critical review. Cell Signal. 2011;23:669–620.
6. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22:233–241.
7. Marie PJ, Dehais F, Hai E. Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol Histopathol. 2002;17:877–885.
8. Hustedt JW, Blizzard DJ. The controversy surrounding bone morphogenetic proteins in the spine: a review of current research. Yale J Biol Med. 2014;87:549–561.
9. US Food and Drug Administration. Premarket Approval (PMA). Infuse bone graft/lt-cage lumbar tapered fusion device. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/cfpmacfmid?P000058. Accessed November 26, 2018.
10. US Food and Drug Administration. Premarket Approval (PMA). Infuse bone graft. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/cfpmacfmid?P000054. Accessed November 26, 2018.
11. Administration USFaD. Premarket Approval (PMA). Infuse Bone graft. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/cfpmacfmid?P050053. Accessed November 26, 2018.
12. Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 2009;302:58–66.
13. Ong KL, Villarraga ML, Lau E, et al. Off-label use of bone morphogenetic proteins in the united states using administrative data. Spine (Phila Pa 1976). 2010;35:1794–1800.
14. US Food and Drug Administration. FDA public health notification: life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. https://wayback.archive-it.org/7993/20170111190511/http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062000.htm. Accessed November 26, 2018.
15. Lord EL, Cohen JR, Buser Z, et al. Trends, costs, and complications of anterior cervical discectomy and fusion with and without bone morphogenetic protein in the united states medicare population. Global Spine J. 2017;7:603–608.
16. Alvin MD, Derakshan A, Lubelski D, et al. Cost-utility analysis of 1- and 2-level dorsal lumbar fusions with and without recombinant human bone morphogenic protein-2 at 1-year follow-up. Clin Spine Surg. 2016;29:E28–E33.
17. El Bialy I, Jiskoot W, Reza Nejadnik M. Formulation, delivery and effects of bone morphogenetic protein-2. Tissue Eng Part B Rev. 2005;11:471–491.
18. Oxford Center for Evidence-Based Medicine Levels of Evidence Scale. https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Accessed November 26, 2018.
19. Boyne PJ, Lilly LC, Marx RE, et al. De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg. 2005;63:1693–1707.
20. Tripplett RG, Nevins M, Marx RE, et al. Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation. J Oral Maxillofac Surg. 2009;67:1947–1960.
21. Kao DW, Kubota A, Nevins M, et al. The negative effect of combining rhBMP-2 and bio-oss on bone formation for maxillary sinus augmentation. Int J Periodontics Restorative Dent. 2012;32:61–67.
22. Kim MS, Lee JS, Shin HK, et al. Prospective randomized, controlled trial of sinus grafting using Escherichia-coli-produced rhBMP-2 with a biphasic calcium phosphate carrier compared to demeprteinized bovine bone. Clin Oral Implants Res. 2015;26:1361–1368.
Kim HJ, Chung JH, Shin SY, et al. Efficacy of rhBMP-2/hydroxyapatite on sinus floor augmentation: a multicenter, randomized controlled clinical trial. J Dent Res. 2013;94(Suppl 9):1588–1658.

Jung RE, Glauser R, Schärer P, et al. Effect of rhBMP-2 on guided bone regeneration in humans. Clin Oral Implants Res. 2005;14:556–568.

Fiorellini JP, Howell TH, Cochran D, et al. Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. J Periodontol. 2005;76:605–613.

Huh JB, Lee HJ, Jang JW, et al. Randomized clinical trial on the efficacy of escherichia coli-derived rhBMP-2 with β-TCP/HA in extraction socket. J Advo Prosthodont. 2011;13:161–165.

de Freitas RM, Susin C, Spin-Neto R, et al. Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts: a proof-of-concept randomized clinical trial. J Clin Periodontol. 2013;40:968–975.

Goomes AM, Mealey BL, Huynh-Ba G, et al. Buccal bone formation after flapless extraction: a randomized, controlled clinical trial comparing recombinant human bone morphogenetic protein 2/absorbable collagen carrier and collagen sponge alone. J Periodontol. 2014;85:525–535.

Kim YJ, Lee JY, Kim JE, et al. Ridge preservation using demineralized bone matrix gel with recombinant human bone morphogenetic protein-2 after tooth extraction: a randomized controlled clinical trial. J Oral Maxillofac Surg. 2014;72:1281–1290.

Nam JW, Khureltogtokh S, Choi HM, et al. Randomised controlled clinical trial of augmentation of the alveolar ridge using recombinant human bone morphogenetic protein 2 with hydroxyapatite and bovine-derived xenografts: comparison of changes in volume. Br J Oral Maxillofac Surg. 2017;55:822–829.

Dickinson BP, Ashley RK, Wasson KL, et al. Reduced morbidity and improved healing with bone morphogenetic protein-2 in older patients with alveolar cleft defects. Plast Reconstr Surg. 2008;121:209–217.

Alonso N, Tanikawa DY, Freitas Rda S, et al. Evaluation of maxillary alveolar reconstruction using a resorbable collagen sponge with recombinant human bone morphogenetic protein-2 in cleft lip and palate patients. Tissue Eng Part C Methods. 2010;16:1183–1189.

Canan LW Jr, da Silva Freitas R, Alonso N, et al. Human bone morphogenetic protein-2 use for maxillary reconstruction in cleft lip and palate patients. J Craniofac Surg. 2012;23:1627–1633.

Neoviux E, Lemberger M, Docherty Skogh AC, et al. Alveolar bone healing accompanied by severe swelling in cleft children treated with bone morphogenetic protein-2 delivered by hydrogel. J Plast Reconstr Aesthet Surg. 2013;66:37–42.

 Arnander C, Westmark A, Veltheim R, et al. Three-dimensional technology and bone morphogenetic protein in frontal bone reconstruction. J Craniofac Surg. 2006;17:275–279.

Shah MM, Smyth MD, Woo AS. Adverse facial edema associated with off-label use of recombinant human bone morphogenetic protein-2 in cranial reconstruction for craniostenosis. Case report. J Neurosurg Pediatr. 2008;1:255–257.

Skogh AC, Kihlström L, Neoviux E, et al. Variation in calvarial bone healing capacity: a clinical study on the effects of BMP-2 hydrogel or bone autograft treatments at different cranial locations. J Craniofac Surg. 2013;24:339–343.

Beidas OE, Deschamps-Braly JC, Morgan AM, et al. Safety and efficacy of recombinant human bone morphogenetic protein 2 on cranial defect closure in the pediatric population. J Craniofac Surg. 2013;24:917–922.

Carter TG, Brar PS, Tolas A, et al. Off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for reconstruction of mandibular bone defects in humans. J Oral Maxillofac Surg. 2008;66:1417–1425.

Herford AS, Boyne PJ. Reconstruction of mandibular continuity defects with bone morphogenetic protein-2 (rhBMP-2). J Oral Maxillofac Surg. 2008;66:616–624.

Balaji SM. Mandibular cystic defect: a composite approach with rhBMP-2 and rib graft. J Maxillofac Oral Surg. 2009;8:27–30.

Herford AS, Cicciù M. Recombinant human bone morphogenetic protein type 2 jaw reconstruction in patients affected by giant cell tumor. J Craniofac Surg. 2010;21:1970–1975.

Misch CM. Bone augmentation of the atrophic posterior mandible for dental implants using rhBMP-2 and titanium mesh: clinical technique and early results. Int J Periodontics Restorative Dent. 2011;31:581–589.

Sweeney L, Lancaster WP, Dean NR, et al. Use of recombinant bone morphogenetic protein 2 in free flap reconstruction for osteonecrosis of the mandible. J Oral Maxillofac Surg. 2012;70:1991–1996.

Cicciù M, Herford AS, Juodzbalys G, et al. Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J Craniofac Surg. 2012;23:784–788.

Cicciù M, Herford AS, Cicciù D, et al. Recombinant human bone morphogenetic protein-2 promote and stabilize hard and soft tissue healing for large mandibular new bone reconstruction defects. J Craniofac Surg. 2014;25:860–862.

Balaji SM. Protein-signaled guided total jaw regeneration in infantile total mandibular resection. Ann Maxillofac Surg. 2014;4:198–200.

Oliveira MR, Gorla LF, Gabrielli MA, et al. Off-label use of bone morphogenetic protein 2 in the reconstructions of mandibular continuity defects. J Craniofac Surg. 2017;28:227–230.

Moslemi N, Khoshkam V, Rafiei SC, et al. Outcomes of alveolar ridge preservation with recombinant human bone morphogenetic protein-2: a systematic review. Implant Dent. 2018;27:351–362.

Kelly MP, Vaughn OL, Anderson PA. Systematic review and meta-analysis of recombinant human bone morphogenetic protein-2 in localized alveolar ridge and maxillary sinus augmentation. J Oral Maxillofac Surg. 2016;74:928–939.

Freitas RM, Spin-Neto R, Marcantonio Junior E, et al. Alveolar ridge and maxillary sinus augmentation using rhBMP-2: a systematic review. Clin Implant Dent Relat Res. 2015;17(Suppl 1):e192–e201.

Calori GM, Mazza E, Colombo M, et al. The use of bone-graft substitutes in large bone defects: any specific needs? Injury. 2011;42(Suppl 2):S56–S63.

Liang F, Leland H, Jedrzejewski B, et al. Alternatives to autologous bone for dental implants using rhBMP-2 and titanium mesh: a systematic review. J Oral Maxillofac Surg. 2016;74:1911–1916.

Cicciù M, Herford AS, Cicciù D, et al. Bone morphogenetic protein-2 substitutes in large bone defects: any specific needs? Injury. 2011;42(Suppl 2):S56–S63.

Haidar ZS, Handy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair: part a: current challenges in BMP delivery. Biotechnol Lett. 2009;31:1817–1824.

Haidar ZS, Handy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair: part b: delivery systems for BMPS in orthopaedic and craniofacial tissue engineering. Biotechnol Lett. 2009;31:1825–1835.

Alonso N, Risco GH, Denadai R, et al. Effect of maxillary alveolar reconstruction on nasal symmetry of cleft lip and palate patients: a study comparing iliac crest bone graft and recombinant human bone morphogenetic protein-2. J Plast Reconstr Aesthet Surg. 2014;67:1201–1208.

Raposo Amaral CE, Denadai R, Alonso N. Three-dimensional upper lip and nostril sill changes after cleft alveolar reconstruction
using autologous bone grafting versus recombinant human bone morphogenetic protein-2. J Craniofac Surg. 2016;27:913–918.

58. Hammoudeh JA, Fahradyan A, Gould BJ, et al. A comparative analysis of recombinant human bone morphogenetic protein-2 with a demineralized bone matrix versus iliac crest bone graft for secondary alveolar bone grafts in patients with cleft lip and palate: review of 501 cases. Plast Reconstr Surg. 2017;140:318e–325e.

59. Raposo-Amaral CE, Denadai R, Alonso N. Three-dimensional changes of maxilla after secondary alveolar cleft repair: differences between rhbmp-2 and autologous iliac crest bone grafting. Plast Reconstr Surg Glob Open. 2015;3:e451.

60. Carstens MH, Chin M, Ng T, et al. Reconstruction of #7 facial cleft with distraction-assisted in situ osteogenesis (DISO): role of recombinant human bone morphogenetic protein-2 with Helistat-activated collagen implant. J Craniofac Surg. 2005;16:1023–1032.

61. Tom WK, Chin M, Ng T, et al. Distraction of rhBMP-2-generated mandible: how stable is the engineered bone in response to subsequent surgeries? J Oral Maxillofac Surg. 2008;66:1499–1505.

62. Franco J, Coppage J, Carstens MH. Mandibular distraction using bone morphogenic protein and rapid distraction in neonates with Pierre Robin syndrome. J Craniofac Surg. 2010;21:1158–1161.

63. Tom WK, Chin M, Ng T, et al. Pretreatment of distraction docking sites with bone morphogenetic protein (rhBMP-2). J Oral Maxillofac Surg. 2009;67:2026–2034.

64. Herford AS, Tandon R, Stevens TW, et al. Immediate distraction osteogenesis: the sandwich technique in combination with rhBMP-2 for anterior maxillary and mandibular defects. J Craniofac Surg. 2013;24:1383–1387.

65. Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med. 2013;158:877–889.

66. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158:890–902.

67. Garg S, McCarthy JJ, Goodwin R, et al. Complication rates after bone morphogenetic protein (BMP) use in orthopaedic surgery in children: a concise multicenter retrospective cohort study. J Pediatr Orthop. 2017;37:e375–e378.

68. Rumalla K, Yarbrough CK, Pugely AJ, et al. Spinal fusion for pediatric spondylolisthesis: national trends, complications, and short-term outcomes. Neurosurgery. 2018;82:701–709.

69. Molinari RW, Kerr C, Kerr D. Bone morphogenetic protein in pediatric spine fusion surgery. J Spine Surg. 2016;2:9–12.

70. Spiro AS, Babin K, Lipovac S, et al. Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series. J Bone Joint Surg Br. 2011;93:695–699.

71. Hissnauer TN, Stiel N, Babin K, et al. Bone morphogenetic protein-2 for the treatment of congenital pseudarthrosis of the tibia or persistent tibial nonunion in children and adolescents: A retrospective study with a minimum 2-year follow-up. J Mater Sci Mater Med. 2017;28:60.

72. Stiel N, Hissnauer TN, Rupprecht M, et al. Evaluation of complications associated with off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in pediatric orthopaedics. J Mater Sci Mater Med. 2016;27:184.

73. Hissnauer TN, Stiel N, Babin K, et al. Recombinant human bone morphogenetic protein-2 (RHBMP-2) for the treatment of nonunion of the femur in children and adolescents: a retrospective analysis. Biomed Res Int. 2017;2017:3046842.

74. Ritting AW, Weber EW, Lee MC. Exaggerated inflammatory response and bony resorption from BMP-2 use in a pediatric forearm nonunion. J Hand Surg Am. 2012;37:316–321.

75. Carragee EJ, Chu G, Rohatgi R, et al. Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am. 2013;95:1537–1545.

76. Lad SP, Bagley JH, Karikari IO, et al. Cancer after spinal fusion: the role of bone morphogenetic protein. Neurosurgery. 2013;73:440–449.

77. Kelly MP, Savage JW, Bentzen SM, et al. Cancer risk from bone morphogenetic protein exposure in spinal arthrodesis. J Bone Joint Surg Am. 2014;96:1417–1422.